Key result
Qili Qiangxin Capsule combined with western medicine significantly improved overall response rate (P<0.00001) and reduced rehospitalization (P=0.0003) compared to western therapy alone.
Why the study?
The study was conducted to evaluate the efficacy and safety of Qili Qiangxin Capsule combined with western medicine in patients with ischemic cardiomyopathy comorbid with heart failure.
Does Qili Qiangxin Capsule combined with western medicine improve clinical and echocardiographic outcomes in patients with ischemic cardiomyopathy comorbid with heart failure?
Meta-Analysis
Does Qili Qiangxin Capsule combined with western medicine improve clinical and echocardiographic outcomes in patients with ischemic cardiomyopathy comorbid with heart failure?
p-value: p=<0.00001
Qili Qiangxin Capsule as an adjuvant to western medicine improves cardiac function, quality of life, and reduces rehospitalization in patients with ischemic cardiomyopathy and heart failure, though it does not significantly reduce mortality.
Supports adjunctive QLQXC for better function, QoL, and fewer rehospitalizations in ICM-HF; extends meta-analytic evidence on surrogates while leaving mortality open.
To evaluate the efficacy and safety of Qili Qiangxin Capsule (QLQXC) combined with western medicine in patients with ischemic cardiomyopathy (ICM) comorbid with heart failure (HF) for clinical application. We searched relevant references in Chinese databases including China National Knowledge Infrastructure (CNKI), China Scientific Journal Database (VIP), Wanfang Database, and China Biology Medicine (CBM), as well as English databases including PubMed and Embase, from the foundation of the database to January 8, 2023, without language restrictions. All statistical analyses, including subgroup and sensitivity analyses, were performed using the Review Manager (version 5.4) and Stata (version 15.0). QLQXC combined with western medicine significantly increased the endpoints of overall response rate (ORR) (P < 0.000 01), left ventricular ejection fraction (LVEF) (P < 0.000 01), the score of Minnesota Living with Heart Failure Questionnaire (MLHFQ) (P = 0.000 2), and 6-minute walking distance (6MWD) (P < 0.000 01), decreased left ventricular end-diastolic diameter (LVEDD) (P < 0.000 01), left ventricular end-systolic diameter (LVESD) (P = 0.03), and pro-brain natriuretic peptide (pro-BNP) (P < 0.00001), and reduced the incidence of rehospitalization (P = 0.0003) and adverse events (AEs) (P = 0.000 6) compared with those under the conventional western therapy alone. Nonetheless, no significant difference was observed in reducing the mortality between the QLQXC combined with western medicine group and the western medicine group (P = 0.30). The combination therapy of QLQXC with western medicine can potentiate cardiac function and raise the quality of life in patients with ICM comorbid with HF.
No takes yet. Share an insight, caveat, or question.
Ziwei et al. (2023) conducted a meta-analysis in Ischemic cardiomyopathy (ICM) comorbid with heart failure (HF). Qili Qiangxin Capsule (QLQXC) combined with western medicine vs. Conventional western therapy alone was evaluated on Overall response rate (ORR) (p=<0.00001). Qili Qiangxin Capsule combined with western medicine significantly improved overall response rate (P<0.00001) and reduced rehospitalization (P=0.0003) compared to western therapy alone.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: